Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo SmithKline

This article was originally published in The Tan Sheet

Executive Summary

Merger of Glaxo Wellcome and SmithKline Beecham likely will not require divestiture of their smoking cessation products, companies announce Dec. 12. Firms have reached an agreement with FTC in which SB will sell worldwide rights for Rx antivirals Vectavir/Denavir (penciclovir) and Famvir (famciclovir) to Novartis. The consent decree has been submitted to FTC and awaits review and approval; Glaxo and SmithKline expect completion of merger Dec. 27

You may also be interested in...



Citrucel Claim That Metamucil Causes Excess Gas Expelled After 20 Years

GlaxoSmithKline will discontinue claim P&G's Metamucil product causes excess gas and it Citrucel doesn't after P&G presented evidence that met NAD's standard for reopening a review. The industry self-regulation organization found GSK could no longer support its claim.

Glaxo Zantac 75 Divestiture To W-L Required By FTC

Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.

Glaxo Zantac 75 Divestiture To W-L Required By FTC

Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS092009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel